<DOC>
	<DOCNO>NCT02065700</DOCNO>
	<brief_summary>The primary objective study evaluate long-term safety tolerability filgotinib ( formerly GLPG0634 ) treatment rheumatoid arthritis . Participants enrol open-label long-term follow-up study complete one two core study , GLPG0634-CL-203 ( DARWIN1 ) GLPG0634-CL-204 ( DARWIN2 ) , evaluated side effect may occur ( long-term safety tolerability ) take filgotinib . During course study , participant also examine long-term effect filgotinib administration disease activity ( efficacy ) , subject ' disability , fatigue , quality life .</brief_summary>
	<brief_title>Long-term Follow-up Study GLPG0634 Active Rheumatoid Arthritis Patients</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Key Male female 18 year age old day signing inform consent Participants complete one qualify core study GLPG0634CL203 GLPG0634CL204 may benefit filgotinib longterm treatment accord Investigator 's judgment Females childbearing potential sexually active men must agree use highly effective method birth control specify protocol , study least 12 week last dose filgotinib Key Participants prematurely withdraw one 2 core study ( GLPG0634CL203 GLPG0634CL204 ) , reason Persistent abnormal lab value one 2 core study ( GLPG0634CL203 GLPG0634CL204 ) , accord Investigator 's judgment Diagnosis rheumatic autoimmune disease inflammatory joint disease rheumatoid arthritis , except secondary Sjogren 's syndrome Any condition circumstance , opinion Investigator , may make participant unlikely unable complete study comply study procedures requirement Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Methotrexate</keyword>
	<keyword>insufficient responder</keyword>
</DOC>